

12 October 2026

ASX Announcement

Firebrick Secures \$732k in Strategic Investments

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that it has secured firm commitments from strategic investors for approximately \$732k, through the placement of approximately 20.9 million fully paid ordinary shares ("**Shares**") at an issue price of \$0.035 (3.5 cents) per share (the "**Placement**").

The investment was anchored by the Company's licensing partner in the Philippines through Pharma Nutria N.A. Inc. ("**PN-NA**"), a member of the S. V. More Group of Companies. The PN-NA investment was \$631,750, which increases PN-NA's holding in Firebrick to just over 10.0%. The remaining \$100,000 is being invested by an existing sophisticated investor who has supported the Company since its listing on the ASX.

These investments follow on from the ASX announcements of 29 September 2026 and 7 October 2026 where the Company announced its intention to enter the US retail pharmacy market for Nasodine products.

Albert-Jan Santillana, President and CEO of the S. V. More Group of Companies, said: "This investment reflects our growing confidence in Firebrick and in the long-term potential of the Nasodine franchise. We are encouraged by the progress being made in the United States and other markets and are equally excited about the opportunity to bring Nasodine to the Philippines. By increasing our investment, we are strengthening a partnership that we believe has significant potential to grow as Firebrick expands the Nasodine portfolio and its presence internationally."

Firebrick CEO and Executive Chairman, Peter Molloy stated: "Firebrick is very pleased to welcome this further investment from our licensing partner in the Philippines. It reflects an important commercial affirmation for the Nasodine franchise and should be seen as very encouraging by all shareholders."

Details of the Placement:

The Company will issue 18,050,000 Shares under the Company's existing 7.1A placement capacity and 2,857,142 Shares under its 7.1 placement capacity. The total Shares to be issued represent approximately 7.28% of current shares on issue (287,198,985). The issue price of \$0.035 per share represents a premium of 21.5% to the 15-day VWAP to 9 October 2026 (\$0.0288) and a 20.7% premium to the last trading place on 9 October 2026, being \$0.029 (2.9 cents).

Receipt of the Placement funds will be staggered and it is expected that the final number of Shares will be issued by 20 October 2026.

No material costs or commissions have been paid in connection with the Placement.

Use of Funds:

Proceeds from the Placement will be applied as follows:

- New production for US retail distribution
- Production and launch in Singapore of a new Nasodine product
- Working capital

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Ltd.

- ENDS -

About Firebrick Pharma

Firebrick Pharma is commercialising Nasodine® Nasal Spray (0.5% PVP-I), which has already been introduced into several markets. It was also recently approved for marketing in Indonesia, and approval in the Philippines is expected. Nasodine® Throat Spray is the first follow-on product in the Nasodine range and is now available in Singapore and soon in the US. Importantly in the US, Firebrick is now expanding from online sales only to actively pursuing retail pharmacy distribution. For further information, visit firebrickpharma.com

Investor contact: Kam Watson, Firebrick Pharma; investors@firebrickpharma.com